High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma

Tumor-specific mutations can result in immunogenic neoantigens, both of which have been correlated with responsiveness to immune checkpoint inhibitors in highly mutagenic cancers. However, early results of single-agent checkpoint inhibitors in multiple myeloma (MM) have been underwhelming. Therefore...

Descripción completa

Detalles Bibliográficos
Autores principales: Miller, A, Asmann, Y, Cattaneo, L, Braggio, E, Keats, J, Auclair, D, Lonial, S, Russell, S J, Stewart, A K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709757/
https://www.ncbi.nlm.nih.gov/pubmed/28937974
http://dx.doi.org/10.1038/bcj.2017.94

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709757/
https://www.ncbi.nlm.nih.gov/pubmed/28937974
http://dx.doi.org/10.1038/bcj.2017.94

Ejemplares similares